No Data
Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Biggest Owners Are Individual Investors Who Got Richer After Stock Soared 4.8% Last Week
Zhejiang Medicine Obtains Registration for Intravenous Solution
Zhejiang Medicine Subsidiary Passes US FDA Inspection for Antibiotic
Zhejiang Medicine (600216.SH): Subsidiary Innovation Biologics passes on-site inspection by the FDA in the USA.
On February 26, Glory Union reported that Zhejiang Medicine (600216.SH) announced that recently, Innovation Biology received the Establishment Inspection Report (EIR) and a letter from the FDA regarding the inspection conducted. Based on the regulations of the USA 21CFR (Title 21 of the Code of Federal Regulations), the FDA confirmed that the inspection has concluded. The letter indicates that Innovation Biology's production quality management system meets the CGMP requirements of the USA FDA, and Innovation Biology successfully passed the routine supervision inspection by the USA FDA. The FDA inspection pertained to the production line for injectable Vancomycin hydrochloride, with a designed capacity of 10 million bottles per year.
Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Shares Not Telling The Full Story
Zhejiang Pharmaceutical: Zhejiang Pharmaceutical 2024 Annual Results Pre-Increase Announcement
The Three-year Shareholder Returns and Company Earnings Persist Lower as Zhejiang Medicine (SHSE:600216) Stock Falls a Further 4.0% in Past Week
